WCLC 2026 at a glance
At IASLC-WCLC 2026, where will the next wave of competitive differentiation in lung cancer emerge? From antibody-drug conjugates (ADCs) and EGFR treatment sequencing to central nervous system (CNS) activity and AI-enabled decision support, WCLC 2026 is set to spotlight strategic questions shaping the evolving lung cancer treatment landscape.
đź“… Build your schedule around the topics that matter most.
📥 Download the IASLC_WCLC_2026_Preview_by_LucidQuest
Key Lung Cancer Treatment Trends to Watch at WCLC 2026
Antibody-Drug Conjugates: B7-H3, TROP2 and HER2 in Lung Cancer
B7-H3, TROP2 and HER2 programmes will test whether antibody-drug conjugates can establish broader roles across small cell lung cancer (SCLC) and non-small cell lung cancer (NSCLC) treatment pathways.
EGFR Treatment Sequencing: ADAURA, PAPILLON and REZILIENT 3
ADAURA, PAPILLON and REZILIENT 3 may clarify how EGFR treatment sequencing evolves across early-stage, advanced and exon 20 insertion NSCLC.
CNS Activity and Brain Metastases in Lung Cancer
Intracranial activity could become increasingly important as targeted therapies and ADCs compete in patients with brain metastases.
Precision Oncology: EGFR, HER2, ALK, ROS1 and RAS Biomarkers
EGFR, HER2, ALK, ROS1 and RAS strategies point toward deeper molecular segmentation and personalised lung cancer treatment, while increasing the complexity of biomarker testing and treatment selection.
Competitor and Industry Signals at WCLC 2026
B7-H3 ADCs: TAISHAN-302 and ARTEMIS-008 in Relapsed SCLC
Phase 3 TAISHAN-302 and ARTEMIS-008 will test whether Tam-Peli and risvutatug rezetecan can establish a new treatment pathway in relapsed SCLC.
AstraZeneca: EGFR, HER2 and CNS Outcomes in Lung Cancer
EGFR, HER2, early-stage disease and CNS outcomes remain central to AstraZeneca’s lung cancer strategy, including the long-term ADAURA update and DESTINY-Lung04.
Emerging Lung Cancer Pipeline: New Assets and Treatment Modalities
YH42946, CGT4255, VRN101099, SYS6010, SNB-101 and DRP-104 add new HER2, biomarker-led and treatment-modality approaches to the competitive landscape.
Artificial Intelligence and Machine Learning at WCLC 2026
AI in Lung Cancer: Clinical Decision Support, Imaging and Pathology
AI agents, imaging, pathology and risk-stratification approaches will be evaluated for their potential to influence precision lung cancer care and clinical decision-making.
Molecular Monitoring: ctDNA, Epigenomic Subtyping and MRD
Circulating tumour DNA (ctDNA), epigenomic subtyping and tissue-free minimal residual disease (MRD) approaches suggest growing convergence between AI-enabled analytics and longitudinal lung cancer monitoring.
What We Are Watching After WCLC 2026
- Whether B7-H3 ADCs deliver sufficient efficacy and safety differentiation to change treatment in relapsed SCLC.
- Whether ADC–immunotherapy and PD-1/VEGF-A combinations generate evidence capable of challenging established checkpoint-inhibitor strategies.
- Whether AI-enabled screening, pathology and molecular monitoring move beyond analytical validation toward routine clinical decision support.
Download the WCLC 2026 Preview Report
Download LucidQuest’s WCLC 2026 preview report for deeper analysis of emerging lung cancer therapies, clinical developments and competitive signals.
đź“… Build your schedule around the topics that matter most.
đź“Ą Download the IASLC_WCLC_2026_Preview_by_LucidQuest
Contact us for end-to-end conference coverage.
